{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04603300",
      "orgStudyIdInfo": {
        "id": "INT301-101"
      },
      "organization": {
        "fullName": "Intrommune Therapeutics",
        "class": "INDUSTRY"
      },
      "briefTitle": "OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut",
      "officialTitle": "Oral Mucosal Escalation Goal Assessment (OMEGA) Study: A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-07",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-05-15",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2023-06-30",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2023-06-30",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-09-25",
      "studyFirstSubmitQcDate": "2020-10-23",
      "studyFirstPostDateStruct": {
        "date": "2020-10-26",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-07-26",
      "lastUpdatePostDateStruct": {
        "date": "2023-07-28",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Intrommune Therapeutics",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": true
    },
    "descriptionModule": {
      "briefSummary": "This is a phase 1, multi-center, randomized, double-blind, placebo-controlled study in adult participants with peanut allergy. Participants will be randomized in a 3:1 ratio to receive either an escalating dose of INT301 or placebo. The treatment group will be blinded to the investigator, participants, and the Intrommune study team."
    },
    "conditionsModule": {
      "conditions": [
        "Peanut Allergy"
      ],
      "keywords": [
        "Peanut allergy",
        "Food allergy",
        "Desensitization",
        "Allergy Immunotherapy",
        "OMIT",
        "OIT",
        "EPIT",
        "SLIT",
        "Oral Mucosal Immunotherapy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "maskingDescription": "Double blind is controlled by IWRS",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 32,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Active treatment",
          "type": "ACTIVE_COMPARATOR",
          "description": "INT301 dosing as determined by cohort assignment",
          "interventionNames": [
            "Drug: INT301"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Placebo as determined by cohort assignment",
          "interventionNames": [
            "Drug: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "INT301",
          "description": "INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste",
          "armGroupLabels": [
            "Active treatment"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Fully functional toothpaste containing no immunotherapy agents",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "To evaluate the safety of INT301 compared to placebo in adult peanut allergic participants as measured by dose escalation during study.",
          "description": "Percentage of participants able to consistently tolerate the protocol-specified highest dose; Incidence of systemic and non-systemic adverse reactions.",
          "timeFrame": "Forty-eight weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "To evaluate pharmacologic requirements as interventions for peanut allergic participants experiencing adverse events on INT301.",
          "description": "Number of participants requiring treatment for systemic reactions related to experimental treatment or placebo; Number of adverse events requiring treatment for systemic reactions related to experimental treatment or placebo; Adherence to study treatment.",
          "timeFrame": "Forty-eight weeks"
        },
        {
          "measure": "To determine the maximally tolerated dose during the up-dosing phase for adults.",
          "description": "Dose amount tolerated without AEs requiring discontinuation for each participant.",
          "timeFrame": "Twenty-six weeks"
        }
      ],
      "otherOutcomes": [
        {
          "measure": "To explore changes in peanut-specific IgG4, IgA, and IgE levels in participants (exploratory outcome).",
          "description": "Change from baseline of peanut-specific IgG4, IgA, and IgE in study subjects (exploratory outcome)",
          "timeFrame": "Forty-eight weeks"
        },
        {
          "measure": "To explore changes in patient response to oral food challenge pre-treatment and post treatment.",
          "description": "Change from baseline of tolerated amount of peanut protein",
          "timeFrame": "Forty-eight weeks"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\nParticipant must be 18-55 years of age inclusive, at the time of signing the informed consent.\n\nFemale participants of childbearing potential or male participants with female partners of child-bearing potential must utilize highly effective birth control method(s) throughout the study and for 30 days after the final dose of study drug. Acceptable methods of contraception include: complete abstinence, male or female condoms with spermicide, oral or implanted contraceptives, or vasectomy.\n\nFor female participants of child-bearing potential: Negative serum beta human chorionic gonadotrophin (HCG) pregnancy test at screening.\n\nCapable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nMeets at least one of the following conditions\n\n* Positive skin prick test (SPT) (wheal at least 3 mm greater than control) AND/OR Peanut specific IgE \\>0.35 kU/L\n* Convincing clinical history of allergic reaction to peanut within 1 hour of ingestion for at least 3 months prior to screening.\n* Failed an oral food challenge (OFC) of \\< 100mg of peanut protein at screening.\n* Participant willing and able to undergo the procedures required by the protocol, including, assessment completion, protocol compliance, and participation in the placebo dosing period(s).\n\nExclusion Criteria:\n\n* History of severe anaphylaxis to peanut, defined as hypoxia, hypotension, or neurologic compromise (cyanosis or oxygen saturations \\< 92% at any stage, hypotension, confusion, collapse, loss of consciousness, or incontinence)\n* Significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease) which would make the subject unsuitable for induction of food reactions\n* Eosinophilic or other inflammatory (e.g. celiac) gastrointestinal disease\n* Psychiatric disorders that the Investigator believes will interfere with study assessments\n* Uncontrolled asthma, defined by at least one of the following conditions:\n\n  * \\- FEV1 \\<80% of predicted, or ratio of FEV1 to forced vital capacity (FEV1/FVC) \\<75% of predicted, with or without controller medications.\n  * \\- Inhaled corticosteroids (ICS) dosing of \\>500mcg daily fluticasone (or equivalent ICS based on NHLBI dosing chart.\n  * \\- One hospitalization in the past year for asthma\n  * \\- An ER visit for asthma within six months prior to screening\n* Planned dental surgery during from screening until study exit\n* Moderate or advanced periodontal disease.\n* Current pregnancy or lactating",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "55 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Hudson-Essex Allergy",
          "city": "Belleville",
          "state": "New Jersey",
          "zip": "07109",
          "country": "United States",
          "geoPoint": {
            "lat": 40.79371,
            "lon": -74.15014
          }
        },
        {
          "facility": "Weiss Medical",
          "city": "Riverdale",
          "state": "New Jersey",
          "zip": "07457",
          "country": "United States",
          "geoPoint": {
            "lat": 40.99399,
            "lon": -74.30348
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "39842774",
          "type": "DERIVED",
          "citation": "Berger WE, Faris N, Weinstein M, Wilding GE, Berglund E. Randomized, placebo-controlled, phase 1 safety study of oral mucosal immunotherapy in adults with peanut allergy. Ann Allergy Asthma Immunol. 2025 Apr;134(4):448-456. doi: 10.1016/j.anai.2025.01.013. Epub 2025 Jan 20."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D021183",
          "term": "Peanut Hypersensitivity"
        },
        {
          "id": "D005512",
          "term": "Food Hypersensitivity"
        }
      ],
      "ancestors": [
        {
          "id": "D000074924",
          "term": "Nut and Peanut Hypersensitivity"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}